Children’s Hospital Los Angeles (CHLA) recently joined other prominent U.S. pediatric centers in the Xplore-2 clinical research study. The medical institutions that may enroll patients in the Xplore-2 Early Feasibility Study also include: Boston Children’s Hospital, Children’s Healthcare of [...]
The potential for Xeltis’ restorative technology in aortic valves will be showcased at the International Society for Minimally Invasive Cardiothoracic Surgery meeting in Vancouver on June 13-16. Doctor Gregory Fontana, CardioVascular Institute Los Robles Hospital, Thousand Oaks, California, will [...]
Preliminary one-year data from the Xplore-1 clinical trial have shown that Xeltis’ restorative pulmonary heart valve has potential for use in RVOT reconstruction. In a presentation at the ECHSA meeting in Cascais, Portugal, trial investigator Professor Tomasz Mroczek from the [...]
Preliminary one-year data from the Xplore-1 clinical trial, evaluating Xeltis’ restorative pulmonary heart, valve will be presented for the first time at the ECHSA meeting in Cascais, Portugal. Trial investigator Professor Tomasz Mroczek from the Children’s University Hospital, Krakow, Poland, [...]
Xeltis’ restorative heart valves are the focus of two presentations at the EuroPCR meeting in Paris. Prof. Martin B. Leon, Columbia University Medical Center, and Prof. Patrick Serruys, Imperial College London, are providing an outline on the developments of Xeltis’ [...]
Xeltis’ restorative heart valve technology will feature in two presentations at the International Conference of Tissue-Engineered Heart Valves (ICTEHV) in Amsterdam on May 18. Prof. Frederick J. Schoen from Harvard Medical School will discuss fundamental science on Endogenous Tissue Restoration, the [...]
Xeltis is one of three Swiss Medtech Award finalists; the only therapeutic medical device company to reach the final selection stage this year. The winner will be announced on June 12, as part of Swiss Medtech Day in Bern. The [...]
A Xeltis team joined children with congenital heart conditions and their families for a playful day focused on activities and sport organized by Dutch patient association Harteraad (previously De Hart&Vaatgroep) on Sunday April 15 in Eindhoven, Netherlands. While games entertained children [...]
Xeltis CEO Laurent Grandidier has been voted Outstanding Executive at the 2018 Global Business Excellence Awards in recognition of his leadership skills. Grandidier won the accolade for his accomplishments as “an outstanding social entrepreneur who is revolutionizing cardiovascular treatment with [...]
Dr Gregory Fontana, National Medical Director for Cardiovascular Research, at the Hospital Corporation of America, Nashville, Tennessee, (US), outlined promising preclinical data on Xeltis’ restorative aortic valves at the Heart Valve Society meeting in New York on April 13. Dr [...]
